Titles
- Billions in estimated Medicare Advantage payments from chart reviews raise concerns1
- Billions in estimated Medicare Advantage payments from diagnoses reported only on health risk assessments raise concerns1
- Bioanalytical method validation1
- Bioavailability studies submitted in NDAs or INDs: general considerations1
- Biocompatibility testing of medical devices: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1
- Biodefense: federal efforts to develop biological threat awareness : report to Congressional requesters1
- Biological product deviation reporting for blood and plasma establishments1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1
- Bipartisan Rx for America's health care: a practical path to reform1
- Bipartisan solutions to improve the availability of long-term care1
- Birthing a slave: motherhood and medicine in the antebellum South1
- Bispecific antibody development programs1
- Black Lung Benefits Program: oversight is needed to address trust fund solvency strained by bankruptcies : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Black Lung benefits program: continued inaction on coal operator self-insurance increases financial risk to trust fund : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Blood glucose monitoring test systems for prescription point-of-care use: guidance for industry and Food and Drug Administration staff1
- Bolabola1
- Bone anchors: premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff1
- Brain Glucose Utilization in Mice with a Targeted Mutation in the Thyroid Hormone alpha or beta Receptor Gene1
- Brain-computer interfaces1
- Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff1